Report
Lenny Van Steenhuyse ...
  • Sandra Cauwenberghs
  • Wim Hoste

KBC Securities Morning Note 11-7-2018 ASIT BB, AVTX NA, IVA FR

ASIT biotech: New Private Placement through CBs announced
Avantium: From dusk till DAWN
Inventiva: Positive DSMB recommendations for SSc and NASH
Underlyings
Asit Biotech SA

Asit Biotech SA. Asit Biotech SA, formerly Biotech Tools SA, is a Belgium- based company that develops products aimed to prevent negative response of the immune system.

Avantium NV

Avantium NV Formerly known as Avantium Holding BV. Avantium NV, formerly Avantium Holding BV, is a company based in the Netherlands engaged in environmental research and development (R&D). The Company develops chemical technologies and production processes to convert bio-based feedstock into sustainable products. The Company's business comprises three segments: Catalysis, Renewable Chemistries, and YXY. Catalysis segment provides catalysis R&D services and systems to chemical, refinery and energy companies, utilizing its Flowrence Technology Platform to devise the appropriate catalyst testing solutions. Renewable Chemistries is the development division with a portfolio of projects focusing on the conversion of biomass to chemical building blocks and plastic materials. The YXY segment comprises the activities of Syviana, the joint venture with BASF SE. The YXY technology is used to convert plant-based sugars into chemical building blocks for plastics, such as polymer polyethylenefuranoate (PEF), and other applications.

Inventiva SA

Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Lenny Van Steenhuyse

Sandra Cauwenberghs

Wim Hoste

Other Reports on these Companies
Other Reports from KBC Securities
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Wim Hoste
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch